MDACC Study No:2010-0241 ( NCT No: NCT01243190)
Title:Ofatumumab Early Treatment for High-Risk Treatment-Naive, Early Stage (0-II) Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Principal Investigator:William G. Wierda
Treatment Agent:Ofatumumab
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if ofatumumab can help to
control CLL/SLL that has not yet been treated. The safety of this drug will
also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Ofatumumab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:GlaxoSmithKline
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
For Clinical Trial Enrollment:713-745-0428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults